Kymera and Gilead Reach Exclusive License for KT-200, Securing $45M Milestone Payment
Kymera Therapeutics (KYMR) announced that Gilead Sciences (GILD) has exercised its option to exclusively license KT-200, oral CDK2 molecular glue degrader development candidate discovered and characterized by Kymera, under their strategic collaboration agreement. As a result, Kymera will realize a $45M milestone payment. Gilead will progress the program into IND-enabling studies to support an IND filing in 2027. CDK2-directed molecular glue degraders represent a novel therapeutic approach designed to selectively remove CDK2, a key driver of tumor growth, rather than just inhibiting its function whilst sparing other CDK family proteins. CDK2 acts as a cyclin E binding partner and drives disease in CCNE1 amplified and over expressed cancers. Traditional CDK2 inhibitors can lack specificity and interfere with closely related proteins, leading to undesired side effects. Degraders have the potential to provide more precise, safe, effective, oral treatments for cancers that rely on CDK2 activity, with the potential to meaningfully improve outcomes for patients, including those with advanced breast cancer where treatment options remain limited. In preclinical testing, KT-200 demonstrated low-nanomolar degradation of CDK2, robust activity in CCNE1 amplified, overexpressed cell lines and in vivo tumor models, brain penetrant potential, and a favorable safety profile. Under the terms of the agreement, Kymera is eligible to receive up to $750M in total payments. To date, Kymera has realized $85M in upfront and option exercise payments. In addition, Kymera may also receive tiered royalties ranging from high single-digit to mid-teens on net product sales under the collaboration. Gilead has global rights to develop, manufacture and commercialize all products resulting from the collaboration.
Trade with 70% Backtested Accuracy
Analyst Views on KYMR
About KYMR
About the author
Kymera's KT-621 Receives FDA Fast Track Designation
- FDA Fast Track Designation: Kymera Therapeutics' KT-621 has received Fast Track designation from the FDA for treating moderate to severe eosinophilic asthma, which will expedite the drug's market entry and enhance the company's competitive position in the respiratory disease sector.
- Clinical Trial Progress: KT-621 is currently being evaluated in two Phase 2b studies, including the BREADTH trial for eosinophilic asthma, with data expected by late 2027, providing critical evidence for the drug's efficacy and safety.
- Dermatology Research: Additionally, Kymera is conducting the BROADEN2 Phase 2b trial for moderate to severe atopic dermatitis, with results anticipated by mid-2027, further enriching the company's product pipeline and expanding market opportunities.
- Stock Price Fluctuation: Despite the FDA designation, Kymera Therapeutics' shares closed at $85.05 on Friday, down 2.63%, indicating a cautious market sentiment regarding the company's future performance, which may affect investor confidence.
Kymera Therapeutics' KT-621 Receives FDA Fast Track Designation
- FDA Fast Track Designation: Kymera Therapeutics' KT-621 has received Fast Track designation from the FDA for treating moderate to severe eosinophilic asthma, which will expedite its clinical development process and address the urgent market need for safe and effective oral therapies.
- Clinical Trial Progress: KT-621 is currently undergoing two global Phase 2b clinical trials targeting moderate to severe eosinophilic asthma and atopic dermatitis, with data expected to be reported by mid-2027 and late 2027, respectively, further validating its therapeutic potential.
- Significant Efficacy: In preliminary clinical trials, KT-621 demonstrated substantial reductions in fractional exhaled nitric oxide (FeNO), indicating its potential in modulating Type 2 inflammation and possibly providing better disease control for patients.
- Strong Market Demand: Despite the availability of various asthma treatments, there remains a significant unmet need, and KT-621, as a once-daily oral therapy, is expected to significantly reduce treatment burden and improve patients' quality of life.
KYMERA THERAPEUTICS INC - GILEAD TO PROGRESS KT-200 INTO STUDIES PREPARING FOR IND FILING IN 2027
Kymera Therapeutics Update: Kymera Therapeutics has advanced its KT-200 program into enabling studies, marking a significant step in its development process.
Focus on 2027: The company is targeting the year 2027 for potential advancements and outcomes related to the KT-200 program.
KYMERA THERAPEUTICS REVEALS GILEAD SCIENCES HAS EXERCISED OPTION TO LICENSE KT-200, AN ORAL CDK2 MOLECULAR GLUE DEGRADER CANDIDATE
Announcement of Collaboration: Kymera Therapeutics has announced a collaboration with Gilead Sciences to develop a new oral CDK2 molecular glue degrader.
Focus on Drug Development: The partnership aims to advance the development of the KT-200 candidate, which targets specific cancer pathways for therapeutic intervention.
Nextech Reduces Stake in Kymera Therapeutics: Analysis
- Transaction Overview: Nextech Invest, Ltd. reduced its stake in Kymera Therapeutics by selling 62,013 shares, valued at approximately $4.19 million, reflecting a cautious management strategy regarding its investment in the company.
- Position Value Change: Despite the sale, the value of Nextech's Kymera position increased by $2.41 million at quarter-end, indicating a positive impact from stock price appreciation on the overall portfolio.
- Asset Allocation Analysis: Kymera now represents 2.1% of Nextech's assets under management, positioning it as a satellite investment compared to the fund's concentrated holdings, highlighting its relatively lower significance in the overall portfolio.
- Market Outlook: Kymera Therapeutics focuses on targeted protein degradation therapies in immunology and oncology; although Nextech trimmed its position, the continued holding indicates confidence in the company's clinical pipeline, suggesting investors should watch for future catalysts.
Nextech Reduces Stake in Kymera Therapeutics
- Transaction Overview: Nextech Invest disclosed in an SEC filing on February 17, 2026, that it reduced its stake in Kymera Therapeutics by 62,013 shares, with an estimated transaction value of $4.19 million, reflecting the company's agile response to market fluctuations.
- Position Value Change: Despite the reduction, the quarter-end value of Kymera's position increased by $2.41 million, indicating a positive impact from stock price appreciation and suggesting Nextech's long-term confidence in the stock.
- Holding Proportion Adjustment: Following this transaction, Nextech's stake in Kymera now represents 2.1% of its assets under management, moving it outside the top five holdings, which highlights the fund's concentrated investment strategy and risk management approach.
- Market Performance Analysis: As of February 17, 2026, Kymera's stock price stood at $84.84, reflecting a 128.5% increase over the past year, significantly outperforming the S&P 500 by 118.13 percentage points, showcasing its strong position in the biotechnology sector.
Kymera's KT-621 Receives FDA Fast Track Designation
- FDA Fast Track Designation: Kymera Therapeutics' KT-621 has received Fast Track designation from the FDA for treating moderate to severe eosinophilic asthma, which will expedite the drug's market entry and enhance the company's competitive position in the respiratory disease sector.
- Clinical Trial Progress: KT-621 is currently being evaluated in two Phase 2b studies, including the BREADTH trial for eosinophilic asthma, with data expected by late 2027, providing critical evidence for the drug's efficacy and safety.
- Dermatology Research: Additionally, Kymera is conducting the BROADEN2 Phase 2b trial for moderate to severe atopic dermatitis, with results anticipated by mid-2027, further enriching the company's product pipeline and expanding market opportunities.
- Stock Price Fluctuation: Despite the FDA designation, Kymera Therapeutics' shares closed at $85.05 on Friday, down 2.63%, indicating a cautious market sentiment regarding the company's future performance, which may affect investor confidence.
Kymera Therapeutics' KT-621 Receives FDA Fast Track Designation
- FDA Fast Track Designation: Kymera Therapeutics' KT-621 has received Fast Track designation from the FDA for treating moderate to severe eosinophilic asthma, which will expedite its clinical development process and address the urgent market need for safe and effective oral therapies.
- Clinical Trial Progress: KT-621 is currently undergoing two global Phase 2b clinical trials targeting moderate to severe eosinophilic asthma and atopic dermatitis, with data expected to be reported by mid-2027 and late 2027, respectively, further validating its therapeutic potential.
- Significant Efficacy: In preliminary clinical trials, KT-621 demonstrated substantial reductions in fractional exhaled nitric oxide (FeNO), indicating its potential in modulating Type 2 inflammation and possibly providing better disease control for patients.
- Strong Market Demand: Despite the availability of various asthma treatments, there remains a significant unmet need, and KT-621, as a once-daily oral therapy, is expected to significantly reduce treatment burden and improve patients' quality of life.
KYMERA THERAPEUTICS INC - GILEAD TO PROGRESS KT-200 INTO STUDIES PREPARING FOR IND FILING IN 2027
Kymera Therapeutics Update: Kymera Therapeutics has advanced its KT-200 program into enabling studies, marking a significant step in its development process.
Focus on 2027: The company is targeting the year 2027 for potential advancements and outcomes related to the KT-200 program.
KYMERA THERAPEUTICS REVEALS GILEAD SCIENCES HAS EXERCISED OPTION TO LICENSE KT-200, AN ORAL CDK2 MOLECULAR GLUE DEGRADER CANDIDATE
Announcement of Collaboration: Kymera Therapeutics has announced a collaboration with Gilead Sciences to develop a new oral CDK2 molecular glue degrader.
Focus on Drug Development: The partnership aims to advance the development of the KT-200 candidate, which targets specific cancer pathways for therapeutic intervention.
Nextech Reduces Stake in Kymera Therapeutics: Analysis
- Transaction Overview: Nextech Invest, Ltd. reduced its stake in Kymera Therapeutics by selling 62,013 shares, valued at approximately $4.19 million, reflecting a cautious management strategy regarding its investment in the company.
- Position Value Change: Despite the sale, the value of Nextech's Kymera position increased by $2.41 million at quarter-end, indicating a positive impact from stock price appreciation on the overall portfolio.
- Asset Allocation Analysis: Kymera now represents 2.1% of Nextech's assets under management, positioning it as a satellite investment compared to the fund's concentrated holdings, highlighting its relatively lower significance in the overall portfolio.
- Market Outlook: Kymera Therapeutics focuses on targeted protein degradation therapies in immunology and oncology; although Nextech trimmed its position, the continued holding indicates confidence in the company's clinical pipeline, suggesting investors should watch for future catalysts.
Nextech Reduces Stake in Kymera Therapeutics
- Transaction Overview: Nextech Invest disclosed in an SEC filing on February 17, 2026, that it reduced its stake in Kymera Therapeutics by 62,013 shares, with an estimated transaction value of $4.19 million, reflecting the company's agile response to market fluctuations.
- Position Value Change: Despite the reduction, the quarter-end value of Kymera's position increased by $2.41 million, indicating a positive impact from stock price appreciation and suggesting Nextech's long-term confidence in the stock.
- Holding Proportion Adjustment: Following this transaction, Nextech's stake in Kymera now represents 2.1% of its assets under management, moving it outside the top five holdings, which highlights the fund's concentrated investment strategy and risk management approach.
- Market Performance Analysis: As of February 17, 2026, Kymera's stock price stood at $84.84, reflecting a 128.5% increase over the past year, significantly outperforming the S&P 500 by 118.13 percentage points, showcasing its strong position in the biotechnology sector.
